Abstract

Phenylketonuria (PKU) management is aimed at preventing neurocognitive and psychosocial dysfunction by keeping plasma phenylalanine concentrations within the recommended target range. It can be questioned, however, whether universal plasma phenylalanine target levels would result in optimal neurocognitive outcomes for all patients, as similar plasma phenylalanine concentrations do not seem to have the same consequences to the brain for each PKU individual. To better understand the inter-individual differences in brain vulnerability to high plasma phenylalanine concentrations, we aimed to identify untreated and/or late-diagnosed PKU patients with near-normal outcome, despite high plasma phenylalanine concentrations, who are still alive. In total, we identified 16 such cases. While intellectual functioning in these patients was relatively unaffected, they often did present other neurological, psychological, and behavioral problems. Thereby, these “unusual” PKU patients show that the classical symptomatology of untreated or late-treated PKU may have to be rewritten. Moreover, these cases show that a lack of intellectual dysfunction despite high plasma phenylalanine concentrations does not necessarily imply that these high phenylalanine concentrations have not been toxic to the brain. Also, these cases may suggest that different mechanisms are involved in PKU pathophysiology, of which the relative importance seems to differ between patients and possibly also with increasing age. Further research should aim to better distinguish PKU patients with respect to their cerebral effects to high plasma phenylalanine concentrations.

Highlights

  • Phenylketonuria (PKU; OMIM 261600) management is aimed at reducing plasma phenylalanine (Phe) concentrations as timely as possible and further keeping them within the recommended target range [1,2,3]

  • The most distinctive examples of this are the reports of untreated or late-diagnosed PKU patients, who have somehow escaped from intellectual disability despite high plasma Phe concentrations [4]

  • This study describes 16 cases of PKU patients without ID, despite a late diagnosis with high plasma Phe concentrations

Read more

Summary

Introduction

Phenylketonuria (PKU; OMIM 261600) management is aimed at reducing plasma phenylalanine (Phe) concentrations as timely as possible and further keeping them within the recommended target range [1,2,3]. None of these guidelines take personalized medicine as a starting point, whereas it can be questioned whether universal plasma Phe target levels would result in optimal neurocognitive outcomes for all individual PKU patients. The mechanism underlying these differences in intellectual outcome between PKU patients still remains to be elucidated, as well as its implications for the optimal treatment of PKU individuals

Objectives
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call